Evolus, Inc.
EOLSHealthcare|Drug Manufacturers - Specialty & Generic|US
$6.80
+0.01 (+0.15%)
DCF Value
$9.13
Cash / Share
$0.63
About
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Stock Price
-5.2%(1Y)
1M
-12.8%
3M
-10.3%
6M
+7.0%
YTD
+2.3%
1Y
-3.5%
3Y
-22.1%
5Y
-9.0%
Pipeline Summary
10 total trials1
Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
Completed: 9Recruiting: 1
Active Trials (1)
BoTox Into the Sternocleidomastoid Muscles (SCM)
NCT06903975Neck Muscle Issue
Phase 4Recruiting
Enrollment: 30 participants
Key Facts
Market Cap$449.5M
Employees334 (+1% YoY)
CEODavid Moatazedi
IPO DateFeb 8, 2018
Beta1.34
52-Week Range$3.86 – $9.31
Avg Volume871,520
ExchangeNASDAQ
Websiteevolus.com
Ownership
Float75.5%
Shares Outstanding66.1M
Recent Insider Trades
MOATAZEDI DAVIDSELL
Sep 2, 2026105,108 shares @ $9.04
Avelar RuiSELL
Mar 20, 20263,119 shares @ $4.75
MOATAZEDI DAVIDSELL
Mar 20, 202613,669 shares @ $4.75
MOATAZEDI DAVIDOPTION EX.
Mar 16, 202667,489 shares
MOATAZEDI DAVIDSELL
Mar 17, 2026116,720 shares @ $4.89
Peers
AEONAEON Biopharma, Inc.
$8.8MRecent News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Nov 5, 2026 · prnewswire.com
Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript
Nov 4, 2026 · seekingalpha.com
What Evolus (EOLS) Said on Its Q3 Earnings Call
Nov 4, 2026 · marketbeat.com
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates
Nov 4, 2026 · zacks.com
Data last updated: Nov 9, 2026, 04:09 AM